Skip Navigation


European Heart Journal Advance Access originally published online on April 24, 2007
European Heart Journal 2007 28(9):1052-1053; doi:10.1093/eurheartj/ehm047
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/9/1052    most recent
ehm047v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Schulze, P. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulze, P. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Chromogranin A: friend or foe of the failing myocardium?

Paul Christian Schulze*

Department of Medicine, Boston University Medical Center, 80 E Concord St, Evans 124, Boston, MA 02115-2526, USA

* Corresponding author. E-mail address: christian.schulze@bmc.org

This editorial refers to ‘Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function’{dagger} by M. Pieroni et al., on page 1117

The first 10% of the full text of this article appears below.

Chronic heart failure is defined as the inability of the heart to meet the circulatory demands of the organism. While cardiac injury, e.g. of ischaemic, toxic, metabolic, or genetic cause, is the initial abnormality, secondary changes occur over the course of the disease affecting most organ systems. This leads to a variety of pathologic changes including endothelial, pulmonary, hepatic, renal, endocrine and skeletal muscle abnormalities, and the state of multi-organ impairment in chronic heart failure is now considered the syndrome of chronic heart failure.1

A neuroendocrine activation has been described early in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Myocardial production of chromogranin A in human heart: a new regulatory peptide of cardiac function
Maurizio Pieroni, Angelo Corti, Bruno Tota, Flavio Curnis, Tommaso Angelone, Barbara Colombo, Maria Carmela Cerra, Fulvio Bellocci, Filippo Crea, and Attilio Maseri
EHJ 2007 28: 1117-1127. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
G. Di Comite, C. M. Rossi, A. Marinosci, K. Lolmede, E. Baldissera, P. Aiello, R. B. Mueller, M. Herrmann, R. E. Voll, P. Rovere-Querini, et al.
Circulating chromogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs TNF-{alpha}-elicited endothelial activation
J. Leukoc. Biol., January 1, 2009; 85(1): 81 - 87.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. C. Cerra, M. P. Gallo, T. Angelone, A. M. Quintieri, E. Pulera, E. Filice, B. Guerold, P. Shooshtarizadeh, R. Levi, R. Ramella, et al.
The homologous rat chromogranin A1-64 (rCGA1-64) modulates myocardial and coronary function in rat heart to counteract adrenergic stimulation indirectly via endothelium-derived nitric oxide
FASEB J, November 1, 2008; 22(11): 3992 - 4004.
[Abstract] [Full Text] [PDF]